GLP-1 medications such as Ozempic aren’t approved to treat binge-eating disorder (BED) in the United States or Australia. Early studies suggest they may reduce binge eating, but the evidence is limited and the safety questions for people with eating disorders are unresolved. Psychological treatment, mainly cognitive behavioral therapy (CBT), remains the recommended first-line option.

GLP-1 medications have drawn attention for suppressing appetite and speeding weight loss, and researchers have begun asking whether they might help with binge eating too. This page covers what they are, what the research shows, what the safety concerns are, and how they compare with established treatments such as treatment for binge-eating disorder.

What are GLP-1 medications and how do they work?

Glucagon-like peptide-1 (GLP-1) is a hormone your body makes that helps regulate blood sugar, appetite and feelings of fullness. GLP-1 receptor agonists mimic it. They were first developed for type 2 diabetes, and some are now approved for weight management.

Examples include semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda). Tirzepatide (Mounjaro) is related and acts on both GLP-1 and another hormone, GIP.

They slow how fast food leaves the stomach, increase fullness, and affect brain areas involved in appetite and food-related motivation. Researchers suspect this may help explain why some people taking them report fewer urges to binge eat. Reducing appetite isn’t the same as treating an eating disorder, though. Binge eating is kept going by many psychological, social and biological processes, and whether GLP-1 medications touch the psychological ones is unclear.

Can GLP-1 medications reduce binge eating?

Possibly. Early research on liraglutide, dulaglutide and semaglutide found reductions in binge eating severity and difficulty controlling eating. Many of those studies were small, had no placebo group, or enrolled people seeking treatment for obesity rather than BED.

In 2026, researchers published a systematic review and meta-analysis of 25 randomized controlled trials with more than 8,000 participants. It found small reductions in binge eating. It also found improvements in loss of control over eating, emotional eating and related behaviors. Some limits matter:

  • Only three of the 25 trials recruited people with diagnosed BED or targeted binge eating. Most enrolled people with overweight or obesity who were taking medication for weight or metabolic conditions.
  • Many measured eating behaviors as secondary outcomes, so they weren’t designed to test whether these drugs treat an eating disorder.
  • Every trial had either some concerns or a high risk of bias.
  • Little is known about what happens after people stop. Whether binge eating stays lower once the appetite effects wear off is an open question.

Research in people with binge-eating disorder

Much less. One small placebo-controlled trial gave liraglutide to 27 adults with BED for 17 weeks. People on liraglutide had reductions in binge eating, but not significantly greater than those on placebo. Liraglutide did cause significantly greater weight loss.

That difference matters. Weight loss isn’t recovery from BED. Someone can lose weight with no change in the psychological symptoms that keep an eating disorder going.

Other small studies report improvements with liraglutide, dulaglutide or semaglutide, but their limits make firm conclusions hard. So GLP-1 medications can influence binge eating behavior, but the evidence isn’t strong enough to call them an effective treatment for BED.

Are GLP-1 medications safe for people with eating disorders?

Not well established. Their effects in people with current or past eating disorders aren’t well understood, and researchers have raised concerns.

Dietary restriction is a well-established contributor to eating disorder symptoms. Because these medications reduce hunger and increase fullness, they may push vulnerable people toward restrictive eating. Side effects such as nausea, vomiting, abdominal discomfort and constipation can also make regular meals harder, and regular eating is central to psychological treatment for BED.

Risks for anorexia and bulimia

Researchers are more concerned about people with anorexia nervosa, atypical anorexia nervosa or bulimia nervosa, especially when severe restriction is already present. Suppressing appetite or encouraging further weight loss could reinforce those behaviors and worsen nutritional and psychological health. Case reports describe a return of restrictive eating in people with a history of anorexia nervosa.

In 2026, an international panel of 45 experts and people with lived experience published consensus recommendations. They advised generally avoiding these medications in people with active eating disorders, especially anorexia nervosa, atypical anorexia nervosa, and bulimia nervosa with marked restriction or substantial weight suppression. They also recommended screening for eating disorder symptoms before prescribing and monitoring during treatment.

Evidence on eating disorders getting worse

Not consistently. A 2026 Australian study followed adults in a specialist weight management service and found no statistically significant worsening in eating disorder symptoms, depression, anxiety or distress over 12 months among those who started a GLP-1 medication. That is somewhat reassuring, but few people started medication, the study was observational, and everyone received multidisciplinary care. The results may not apply to people taking these medications without ongoing psychological support.

Use is already happening. A 2026 US study of 436 people with eating disorders found about one-third had used a GLP-1 medication, and about 10% reported misuse. The sample wasn’t nationally representative, so these aren’t prevalence figures for everyone with an eating disorder.

So the evidence doesn’t show these medications routinely cause or worsen eating disorders. It also doesn’t show they’re safe for everyone. The National Eating Disorders Collaboration in Australia stresses the uncertainty and the need for careful clinical oversight.

No. Psychological treatment remains the recommended first-line approach, supported by decades of research and clinical guidelines. CBT has the strongest evidence. It targets the thoughts and behaviors that keep binge eating going, rather than relying mainly on appetite suppression.

How do GLP-1 medications compare with Vyvanse?

GLP-1 medicationsLisdexamfetamine (Vyvanse)
Approved for BEDNoYes. US: moderate-to-severe BED in adults. Australia: adults when non-medication treatment has been unsuccessful or isn’t available, and a psychiatrist should start and manage treatment
Evidence in BEDLimited and earlySeveral randomized controlled trials show reduced binge eating
Main cautionsPossible restriction, side effects, unknown long-term effectsStimulant: raises heart rate and blood pressure, boxed warning for misuse and dependence, can reduce appetite, needs a medical check first

There isn’t enough evidence to say whether GLP-1 medications work better or worse than Vyvanse or psychological treatments. Psychological therapies have a much stronger evidence base and remain the starting point. This reflects the research as of November 2026.

For benefits, risks and what happens when it stops, see Vyvanse for binge eating.

If you already take a GLP-1 medication

Many people with BED or another eating disorder take a GLP-1 medication for something else, such as type 2 diabetes. Having an eating disorder doesn’t automatically mean you should stop a medication prescribed for a legitimate medical reason. Your prescriber does need to know about any current or past eating disorder symptoms. That lets them assess risks, monitor your eating and well-being, and coordinate with an eating disorder specialist if needed.

Talk to your clinician if you notice more dietary restriction, growing concern about weight or shape, trouble eating regularly, or a return of past eating disorder behaviors. Decisions about starting, continuing or stopping medication should be made with medical guidance.

When to get help

See a health professional if binge eating or restriction is affecting your health, relationships or daily life. If you purge, restrict severely or have thoughts of harming yourself, get help now.

Common questions

Can Ozempic stop binge eating?

It isn't approved for that. Early studies show reductions in binge eating, but a small placebo-controlled trial in BED found no significant benefit over placebo.

Is Wegovy approved for binge-eating disorder?

No. Wegovy is approved for weight management, not for BED.

Can GLP-1 medications cause an eating disorder?

The evidence doesn't show they routinely do. Experts advise caution, screening and monitoring, especially in people with restriction or a history of anorexia nervosa.

What is the best treatment for BED?

Psychological treatment, most often CBT, is the first-line treatment. See the best treatment for binge-eating disorder.

Footnotes

  1. Therapeutic Goods Administration. Medicines containing GLP-1 and dual GIP/GLP-1 receptor agonists: approved indications. 2025. ↩

  2. US Food and Drug Administration. Wegovy (semaglutide) prescribing information. 2026. ↩

  3. Emptage I, Kozmér S, Cobham-Wilson A, et al. The effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on binge eating in patients with obesity: a systematic review and meta-analysis. eClinicalMedicine. 2026:104007. doi:10.1016/j.eclinm.2026.104007 ↩ ↩2

  4. Allison KC, Chao AM, Bruzas MB, et al. A pilot randomized controlled trial of liraglutide 3.0 mg for binge eating disorder. Obes Sci Pract. 2023;9:127-136. ↩

  5. Aoun L, Almardini S, Saliba F, et al. GLP-1 receptor agonists: a novel pharmacotherapy for binge eating (binge eating disorder and bulimia nervosa)? A systematic review. J Clin Transl Endocrinol. 2024;35:100333. ↩

  6. Bartel S, McElroy SL, Levangie D, Keshen A. Use of glucagon-like peptide-1 receptor agonists in eating disorder populations. Int J Eat Disord. 2024;57:286-293. ↩ ↩2

  7. Keshen A, et al. Consensus-based clinical and research recommendations for use of glucagon-like peptide-1 receptor agonists in the context of eating disorders: a modified Delphi study. World Psychiatry. 2026;25:465-474. ↩

  8. Maynard S, Hay P, Chimoriya R, et al. Effects of GLP-1 receptor agonist therapy on eating disorder risk and psychological distress in adults with class 3 obesity. Int J Eat Disord. 2026;59:276-286. ↩

  9. Peiper NC, Zibbell JE, LaJoie AS, et al. Use and misuse of GLP-1 receptor agonists among people with eating disorders. JAMA Psychiatry. Published online June 24, 2026. doi:10.1001/jamapsychiatry.2026.1716 ↩

  10. National Eating Disorders Collaboration. Eating disorders and GLP-1 RAs. ↩

  11. National Institute for Health and Care Excellence. Eating disorders: recognition and treatment. NG69. ↩

  12. Ralph AF, Brennan L, Byrne S, et al. Management of eating disorders for people with higher weight: clinical practice guideline. J Eat Disord. 2022;10:121. ↩

  13. US Food and Drug Administration. Vyvanse (lisdexamfetamine dimesylate): prescribing information. Revised April 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021977s052lbl.pdf ↩ ↩2

  14. Therapeutic Goods Administration. Vyvanse (lisdexamfetamine dimesilate): product information (AusPAR PM-2016-01092-1-1). 2018. https://www.tga.gov.au/sites/default/files/auspar-lisdexamfetamine-dimesilate-180515-pi.pdf ↩